8 completed, 3 unknown. 11 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 8, Unknown 3 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
Follow NAFLD: new trials by email Literature Review of NAFLD trials Research Report on NAFLD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study) Essential Amino Acid Supplement by Amino Co, Placebo - Hepatic Steatosis, NAFLD | Phase 3 | Completed | University of Colorado, Denver | 31 | 2024-06-18 | 2026-08-31 |
| An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH) Saroglitazar, Vitamin E, Combination drug - NAFLD | Phase 3 | Unknown | Asian Institute of Gastroenterology, India | 250 | 2021-01-31 | 2021-01-26 |
| The Influence of Probiotic Supplementation on Depressive Symptoms, Inflammation and Oxidative Stress Parameters and Faecal Microbiota in Patients With Depression Depending on Metabolic Syndrome Comorbidity Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175, placebo - Depressive Disorder, Depression | Phase 3 | Unknown | Medical University of Lodz | 200 | 2020-12-17 | 2021-02-16 |
| Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease Lubiprostone 24Mcg Oral twice daily - NAFLD | Phase 3 | Completed | Helwan University | 116 | 2020-11-01 | 2023-12-13 |
| Safety and Tolerability of Novel Medical Nutrition Products for NAFLD Treatment Specialized product for medical nutrition (SPP-1), individualized diet - NAFLD, NASH - Nonalcoholic Steatohepatitis | Phase 2 / Phase 3 | Unknown | Russian Academy of Medical Sciences | 45 | 2020-03-20 | 2021-02-03 |
| Comparison of the Effects of Metformin and Pioglitazone on Liver Enzymes and Ultrasound Changes in Non-Diabetic Non-Alcoholic Fatty Liver Metformin and Pioglitazone - NAFLD | Phase 3 | Completed | King Edward Medical University | 96 | 2019-06-06 | 2022-08-30 |
| Treating PCOS With Semaglutide vs Active Lifestyle Intervention Semaglutide 3mg and 7mg [Rybelsus], Weight loss diet - PCOS, Adolescent Obesity | Phase 2 / Phase 3 | Completed | University of Colorado, Denver | 60 | 2019-05-03 | 2025-11-25 |
| Impact of a Specific Micronutrient-probiotic-supplement on Fatty Liver of Patients After Mini-Gastric Bypass Surgery Micronutrient-probiotic-combination, Micronutrient-placebo-combination - Obesity, Gastric Bypass | Phase 3 | Completed | Bonn Education Association for Dietetics r.A., Cologne, Germany | 60 | 2018-08-31 | 2020-09-25 |
| Hydroxytyrosol and Vitamin E in Pediatric NASH Hydroxytyrosol plus Vitamin E, Placebo - NAFLD | Phase 3 | Completed | Bambino Gesù Hospital and Research Institute | 80 | 2017-04-01 | 2018-07-17 |
| Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents Resveratrol, Placebo - NAFLD, TYPE 2 DIABETES | Phase 2 / Phase 3 | Completed | University of Manitoba | 10 | 2015-08-01 | 2017-05-05 |
| DHA and Vitamin D in Children With Biopsy-proven NAFLD DHA plus Vitamin D, Placebo - NAFLD, Non Alcoholic Steatohepatitis (NASH) | Phase 3 | Completed | Bambino Gesù Hospital and Research Institute | 66 | 2014-01-01 | 2016-01-14 |
Non-alcoholic Fatty Liver Disease (11) · Fatty Liver (2) · Metabolic Syndrome (2) · Obesity (2) · Pediatric Obesity (2) · Anxiety Disorders (1) · Depression (1) · Depressive Disorder (1) · Diabetes Mellitus, Type 2 (1) · Inflammation (1) · Insulin Resistance (1)
Digestive System Diseases (11) · Liver Diseases (11) · Fatty Liver (9) · Nutritional and Metabolic Diseases (6) · Pathological Conditions, Signs and Symptoms (5) · Body Weight (4) · Nutrition Disorders (4) · Overnutrition (4) · Overweight (4) · Signs and Symptoms (4) · Glucose Metabolism Disorders (3) · Hyperinsulinism (3) · Metabolic Diseases (3) · Insulin Resistance (2) · Obesity (2)
Vitamin E (2) · 3,4-dihydroxyphenylethanol (1) · Diet, Reducing (1) · Drug Combinations (1) · Lubiprostone (1) · Metformin (1) · Pioglitazone (1) · Resveratrol (1) · Vitamin D (1) · alpha-Tocopherol (1) · saroglitazar (1) · semaglutide (1)
Bambino Gesù Hospital and Research Institute (2) · University of Colorado, Denver (2) · Asian Institute of Gastroenterology, India (1) · Bonn Education Association for Dietetics r.A., Cologne, Germany (1) · Helwan University (1) · King Edward Medical University (1) · Medical University of Lodz (1) · Russian Academy of Medical Sciences (1) · University of Manitoba (1)
Italy (2) · United States (2) · Canada (1) · Egypt (1) · Germany (1) · India (1) · Pakistan (1) · Poland (1) · Russia (1)
Brandy A Wicklow, MD, MSc (1) · Dr. Mohammad Ibrahim, MBBS, MD (1) · Karl Peter Rheinwalt, MD (1) · Melanie Cree, MD, PhD (1) · Melanie Cree-Green, MD, PhD (1) · Valerio Nobili, Professor (1) · Vasily Isakov, Professor (1)
PMID 33060043, PMID 33804999, PMID 34919684, PMID 35596633, PMID 38732635, PMID 39089652, PMID 39339810, PMID 39683419, PMID 39744921, PMID 40520599, PMID 41177800, PMID 41484701, PMID 42014131
R01DK120612 (1), R44DK135312 (1)